Carboxyl-enriched molecularly imprinted interface with enhanced electrostatic binding for ultrasensitive oxytocin detection in a portable electrochemical platform.
This study presents a new portable sensor for detecting oxytocin with a detection limit of 1.15 pg/mL, which may enhance monitoring in maternal health.
Where it sits
this study against the rest of the oxytocin corpusSummary and findings
A portable electrochemical sensing platform was developed for ultrasensitive detection of oxytocin in maternal serum. The sensor achieved a low detection limit of 1.15 pg/mL and a linear range of 10 - 1000 pg/mL. Clinical serum samples showed strong agreement with ELISA results (r > 0.95).
Abstract
Oxytocin is a key peptide hormone regulating pregnancy and parturition, yet its accurate quantification remains challenging due to its ultra-low abundance and poor stability. Here, we report a portable electrochemical sensing platform based on an electrostatically engineered molecularly imprinted polymer interface for ultrasensitive OT detection in maternal serum. Pyrrole-2-carboxylic acid (P2CA) was rationally selected as the functional monomer to introduce carboxyl groups that enhance interfacial negative charge density, thereby strengthening electrostatic interactions with OT and improving binding affinity. Compared with conventional pyrrole-based systems, the P2CA-based MIP sensor exhibits a wide linear range of 10 - 1000 pg/mL with a low detection limit of 1.15 pg/mL. Molecular simulations combined with high-ionic-strength experiments reveal that electrostatic adsorption dominates the recognition mechanism and underpins the enhanced sensitivity. Integration of petal-shaped gold nanoparticles further increases surface area and conductivity, which amplify the electrochemical signal. The sensor is incorporated into a compact portable device enabling rapid detection (<15 min) with microliter sample volumes (30 μL). It demonstrates excellent selectivity, stability, and mechanical robustness. This system was validated using clinical serum samples, which show strong agreement with ELISA (r > 0.95). These results highlight its potential for point-of-care diagnostics and maternal health monitoring.
Background
The paper addresses the challenge of accurately quantifying oxytocin, a peptide hormone crucial for pregnancy and parturition, due to its low abundance and instability. Previous methods for detection may not have achieved the sensitivity required for clinical applications. This study introduces a novel electrochemical sensing platform that could enhance detection capabilities, making it relevant for maternal health monitoring.
Methods
The study describes a portable electrochemical sensing platform based on a molecularly imprinted polymer interface. The sensor was designed to detect oxytocin in maternal serum with a focus on enhancing binding affinity through electrostatic interactions. Specific details on sample size, population, and duration were not reported in the abstract.
Results
The primary endpoint was a detection limit of 1.15 pg/mL for oxytocin, with a linear detection range of 10 - 1000 pg/mL. The sensor demonstrated strong correlation with ELISA results (r > 0.95), indicating high reliability. Additional performance metrics such as rapid detection time (<15 min) and low sample volume (30 μL) were also noted.
Interpretation
The findings suggest that the new sensing platform offers improved sensitivity compared to conventional methods, potentially filling a gap in current oxytocin detection technologies. However, the clinical significance of the detection limits and the practical application in real-world settings require further validation. Limitations such as the absence of detailed methodology and sample size restrict the robustness of the conclusions drawn.
Key findings
- Detection limit of 1.15 pg/mL for oxytocin.
- Linear range of 10 - 1000 pg/mL.
- Strong agreement with ELISA (r > 0.95).
- Rapid detection time of less than 15 minutes.
- Sample volume required is 30 μL.
Limitations
- Not reported in abstract.
- Details on sample size not provided.
- No information on clinical trial phases or follow-up.
- Potential confounding factors not discussed.